BACKGROUND: Raloxifene and tamoxifen are Food and Drug Administrationeapproved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force recommended these drugs for breast cancer risk reduction in high-risk women. Information on the use of raloxifene and tamoxifen for breast cancer risk reduction in the general population indicates that the risk is believed to be low; however, there is little literature. OBJECTIVE: The purpose of this study was to assess the use of breast cancer risk reduction medications by breast cancer risk level in an older cohort of women. STUDY DESIGN: Women who were enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were assessed for the use of raloxifene, tamoxifen, and other medications. The data sources for use of the drugs were a mailed medication use questionnaire in 2013 and linked Medicare Part D claims files from 2010e2014. Estimated breast cancer risk within 5 years was assessed with the use of the modified Gail model and self-reported breast cancer risk factors; comorbidities were assessed through a questionnaire. RESULTS: A total of 22,235 women completed the medication use questionnaire; of these, 13,640 women (61%) had linked Part D data. In
C
hemoprevention is a potential strategy for reducing morbidity and death from breast cancer. Tamoxifen and raloxifene have both been demonstrated to reduce breast cancer incidence and both currently are Food and Drug Administration (FDA)eapproved for that purpose. [1] [2] [3] Raloxifene, which was previously approved (in 1997) for osteoporosis treatment and prevention, was approved by the FDA in 2007 for breast cancer risk reduction in postmenopausal women who either had osteoporosis or were at high risk for invasive breast cancer. 4 High risk was defined as at least 1 breast biopsy that showed lobular carcinoma in situ or atypical hyperplasia, a 5-year predicted breast cancer risk of at least 1.66% based on the Gail Model, or a first-degree relative with breast cancer. Adverse effects of raloxifene were noted, including risk of venous thromboembolism. Tamoxifen was approved by the FDA in 1998 for breast cancer risk reduction high-risk women; it had been approved previously for treatment of breast cancer. 5 In September 2013, the US Preventive Services Task Force (USPSTF) gave a "B" recommendation for the use of breast cancer riskereducing medications, which included tamoxifen and raloxifene, in women at increased risk for breast cancer. Specifically, for women aged 50 years, the USPSTF concluded that "many women with an estimated 5-year breast cancer risk of 3% or greater are likely to have more benefit than harm from using tamoxifen or raloxifene." 6 Notwithstanding the FDA approvals and USPSTF recommendation, population usage rates of tamoxifen and raloxifene for breast cancer risk reduction are believed to be low; however, the literature on such usage rates is sparse. 7, 8 A few published reports show limited overall use among postmenopausal women. 8, 9 To our, there are no published data on population usage rates of raloxifene by breast cancer risk level.
In this study, we assessed the use of raloxifene and tamoxifen as a function of breast cancer risk level, osteoporosis status, and time period (before and after the USPSTF recommendation) in a large cohort of older women, specifically, women who were enrolled in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The PLCO trial was a randomized trial that examined the effect of screening for 4 cancers that was undertaken at 10 centers across the United States. Data on prescription medication use were available from 2 main sources: self-reported use from a questionnaire administered in 2013 and prescription data from linked Medicare Part D for 2010e2014. In addition, information on the factors that were used to predict breast cancer risk and osteoporosis status was available from questionnaire data. Therefore, the PLCO cohort allowed for the assessment of the use of breast cancer riskereducing medications in relation to breast cancer risk over the time period of the USPSTF recommendation. For context, we also assessed the use of statins in this population, as another example of a class of drugs approved for disease risk reduction.
Methods

The PLCO trial design
The design of the PLCO trial has been described previously. 10 Briefly, the trial was designed to determine the effect of specific screening tests on cause-specific mortality rates. Enrollment at 10 US screening centers was carried out from 1993e2001. Women were considered eligible if they were between ages 55 and 74 years and had no previous diagnosis of lung, colorectal, or ovarian cancer. Two initial PLCO trial exclusion criteria (previous oophorectomy and current tamoxifen use) were dropped in 1996 and 1999, respectively. Women were screened for lung cancer with chest radiographs annually for 4 years, for ovarian cancer with CA-125 annually for 6 years and with transvaginal ultrasound scans annually for 4 years, and for colorectal cancer with sigmoidoscopy at baseline and year 3 or 5. Women with previous bilateral oophorectomy were included in the trial and screened for lung and colorectal cancer, but not ovarian cancer. All subjects provided informed consent, and each screening center's institutional review board approved the trial.
According to the original trial design, women were followed at each screening center for up to 13 years for all-cancer incidence and death. In 2011, the PLCO trial transitioned to centralized follow-up evaluation, with subjects having to reconsent to continue active follow up, to switch to passive follow up, or to refuse further follow up. Only the active follow-up group could be contacted with further questionnaires or consent requests. Active and passive participants continued to be followed for death and cancer incidence through linkage with the National Death Index and state cancer registries.
Baseline and supplemental questionnaires
A baseline questionnaire was administered at randomization and a supplemental questionnaire (SQX) was administered in 2006e2007, corresponding to study years 6e13. Together, these questionnaires inquired about the breast cancer risk factors used in predictive models and comorbidities that included osteoporosis, high cholesterol, diabetes mellitus, and history of heart attack or stroke.
Breast cancer risk model
The breast cancer risk model used here is the Gail Model, which was updated in 2012 and is available on the National Cancer Institute website and which is mentioned in the USPSTF statement as a model that can be used to assess breast cancer risk level. 11 The model includes the following factors: current age, age at first live birth, age at menarche, family history of cancer in a first-degree relative, number of previous breast biopsies, and race/ethnicity. To apply the model, race/ethnicity and ages at first live birth and menarche were derived from the corresponding baseline questionnaire variables. Number of breast biopsies was derived from the SQX responses. Family history was included in both the baseline questionnaire and SQX; the SQX value was used if the data were not missing, otherwise, the baseline questionnaire variable was used. Current age was age at the time medication use was being assessed. The Gail Model also included BRCA1-2 mutation status, which was not available for the PLCO trial, and was presumed negative since the prevalence of BRCA mutations is under 0.5% in the general population. The 5-year risk of breast cancer (BrCa 5 ) was computed and used in the analysis.
Medication information
Information on prescription medication use came from 2 sources. First, a medication use questionnaire (MUQ) was administered in 2013. The MUQ asked participants to list all prescription drugs taken during the past 30 days. For each listed drug, respondents also filled in number of years taken and number of days taken per month. The second source came from linked Medicare Part D (prescription drug) data. Participants who were receiving the MUQ were asked to consent to have their study data linked to Medicare claims data. For those consenting, enrollment and claims data were linked for the years 2010e2014. Medicare Part D data include information on months of coverage, prescriptions filled (not actual use), and days' supply for each prescription.
In addition, the SQX, in a section on women's health issues, included the question "Did you ever take any of the following medications to strengthen your bones or for any other reason" and listed 8 specific medications that included raloxifene and tamoxifen and various bisphosphonates. For each medication, there was a question on whether the woman ever took the drug and whether they were currently taking it. The SQX data were used to assess duration of use among women with medication as reported from Part D. Figure 1 shows a flowchart of who was included in the cohort for this analysis. The analysis cohort consisted of all women who completed the MUQ and who were under age 85 years with no history of breast cancer at that time; they also had to have a computable breast cancer risk score. To have been eligible for the MUQ, women previously must have been eligible for and chosen to transfer to active follow-up status (Figure 1 ). Of the analysis cohort, a subset had useable Part D data (specifically, women who consented to Medicare linkage and had Part D coverage for 12 months during 2010e2014).
Analysis cohort
To assess the representativeness of the analysis cohort within the PLCO trial, we compared their baseline demographics with those of the cohort in the PLCO trial who potentially could have been included in the analysis cohort but were not. Specifically, this was all women who were eligible for active transfer status in 2011, who were alive, who were under ajog.org GYNECOLOGY Original Research age 85 years, and who had no history of breast cancer in 2013. Thus, this included women who were eligible for, but who did not choose, active follow-up status and women who were eligible for, but did not participate in, the MUQ.
Quantitative methods
From the MUQ, the medication usage rate was defined as the proportion of women who reported use during the previous month; from Part D, it was defined as the proportion who filled any prescription from 2010e2014. We examined usage rates of raloxifene and tamoxifen by BrCa 5 level and by osteoporosis status for raloxifene. For BrCa 5 , we used the categories of <1.66%, 1.66e3.0%, and 3.0% based on the FDA and USPSTF recommended cutoffs. To examine the intensity of medication use from Part D, we added up the total days' supply of raloxifene (or tamoxifen) over all filled prescriptions during the coverage period and divided this by the total number days of Part D coverage to produce a daily usage rate.
To analyze time trends in Part D data from 2010e2014, we developed a longitudinal generalized estimating equation model (Proc Genmod, version 9.4; SAS Institute Inc, Cary, NC) with 1 observation per person per calendar year of Part D coverage and use (prescription claim) of raloxifene (or tamoxifen) per year as the outcome variable. The model accounts for within-person correlation based on the repeated statement and an autoregressive correlation matrix. The model controlled for age, breast cancer risk score, and osteoporosis status. We also specifically examined the change in use between 2012 and 2014 (ie, between the year before and after the USPSTF recommendation was issued).
For context, we also assessed the use of other drugs, specifically oral bisphosphonates and statins. Bisphosphonates, like raloxifene, are used to treat osteoporosis, and statins are an example of another drug class approved for disease risk reduction, in this case cardiovascular disease.
Finally, to assess the concordance between the MUQ and Part D data, we compared MUQ responses with Part D claims over a similar time period. Because the majority of raloxifene and tamoxifen prescriptions were for 90 days, we used the 90-day period before the MUQ survey date for Part D claims. The kappa statistic was used to measure concordance.
Results
Analysis cohort
Of 78,215 women enrolled in the PLCO trial, 22,235 women were included in the analysis cohort ( Figure 1 ). All of the 22,235 were age 65 years by 2013 and were Medicare eligible for 12 months from 2010e2014, which was the period with Part D data. Of the analysis cohort, 18,158 women (81.7%) consented for linkage with Center for Medicare and Medicaid Services. Of those who consented, 103 women (0.6%) could not be matched to a Medicare record, 4094 women (22.5%) had a Medicare record but no Part D coverage, and 321 women (1.8%) had <12 months of Part D coverage, which left 13,640 women (75.1%) who were included in the Part D analysis based on 12 months of Part D coverage. Among these 13,640 women, the mean length of coverage was 4.4 years, with 71% having coverage for the entire 5-year period. 
Study flowchart
Flowchart shows which women with lung, colorectal and ovarian cancer were eligible for the current analysis. Years (parentheses) indicate the time of the event. To be eligible for transfer to active centralized follow-up evaluation in 2011, subjects had to be alive, not lost to follow up, and not at the University of Alabama at Birmingham; University of Alabama at Birmingham subjects were transferred to centralized follow up later and were not eligible for the medication use questionnaire. Having part D coverage was defined as at least 12 months of coverage during the period. Boxes with colored type represent women who were included in the overall analysis (blue type) and the subanalysis of Medicare claims data (purple type). Original Research GYNECOLOGY ajog.org Table 1 gives the baseline characteristics of the analysis cohort. Most women (92.1%) were non-Hispanic white;20% of them were age 65 years at enrollment, and 38.2% of them were college educated. At the time of the MUQ, 45% of the women were 75e84 years old, and the rest of the women (55%) were 65e74 years old. As compared with the potentially eligible (but excluded) cohort, the analysis cohort was more non-Hispanic white (92.1% vs 83.6%) and more likely to be a college graduate (38.2% vs 23.8%). There was no difference in family history of breast cancer (13.6% vs 13.2%). Within the analysis cohort, those women with Part D data were similar to the overall cohort (Table 1) .
Among all women, 36.5% had BrCa 5 <1.66%; 45.2% had BrCa 5 within 1.66e3.0%, and 18.2% had BrCa 5 3.0% (Table 2) . Table 2 shows the results of the MUQ medication analysis. Usage rates were 2.5%, 4.0%, and 2.1% for all women, women with osteoporosis, and women without osteoporosis, respectively. Among all women and among women with and without osteoporosis, raloxifene use significantly increased with BrCa 5 level; usage rates for all women were 1.8%, 2.5%, and 4.0% for BrCa 5 <1.66%, 1.66e3.0%, and 3.0%, respectively (probability value trend, <.0001). Women without osteoporosis and BrCa 5 3.0% had a usage rate of 3.6%. Overall rates of raloxifene use from the MUQ were similar among women who were included in the part D analysis (2.6%) as for women not included (2.4%). Among reported raloxifene users, 97.3% reported usage of 30 days in the past month. For duration of use, 75% of users had used the drug for at least 6 years; this proportion did not statistically differ by osteoporosis status or BrCa 5 level.
Raloxifene use
Overall, older women (75e84 vs 65e74 years) had significantly higher rates of osteoporosis but lower overall rates of raloxifene use, although not statistically significantly so. When we controlled for osteoporosis status, raloxifene use was border significantly lower among older women (odds ratio, 0.84; 95% confidence interval, 0.7e1.0).
Patterns of raloxifene use by breast cancer risk and osteoporosis status from Part D data were similar to those observed with MUQ data, with rates higher among women with elevated BrCa 5 levels and with osteoporosis ( Table 2) . Among all women, raloxifene use was 3.3%, 4.0%, and 6.6% for BrCa 5 levels of <1.66%, 1.66e3.0% and 3.0%, respectively (probability value trend, <.0001). Among women without osteoporosis, those with BrCa 5 3.0% had a raloxifene usage rate of 5.2%, compared with 2.9% in women with BrCa 5 <3.0% (P<.0001). Among all raloxifene users without osteoporosis, 28% (98/353 women) had BrCa 5 levels of 3.0%. Among ever-users of raloxifene from Part D data (n¼577), 45.1% of the women had a daily use rate >75%; 20.5% of the women had a rate <25%, and the rest of the women (34.5%) had a rate in from 25e75%. The proportion with daily use rates >75% increased with increasing BrCa 5 level; proportions were 37.6%, 45.8%, and 51.5% for BrCa 5 <1.66%, 1.66e3.0%, and 3.0%, respectively (probability value trend, (Table 3) .
Overall, the odds ratio for raloxifene use in the current vs previous year was 0.90 (95% confidence interval, 0.87e0.92). The model comparing use in 2014 vs 2012 also showed significant decreases among all groups; the overall odds ratio was 0.77 (95% confidence interval, 0.71e0.83) and the odds ratio for women with BrCa 5 3.0% and no osteoporosis was 0.73 (95% confidence interval, 0.60e0.90).
With the use of the SQX medication data from 2006e2007, the decrease in use from 2012e2014 was assessed in relation to past use at a time After assessment for the concordance of the MUQ and Part D sources of raloxifene use for the same time period, the kappa statistic was 0.88 (95% confidence interval,0.85e0.91). Table 4 shows rates of tamoxifen use by BrCa 5 category. From the MUQ, rates for the BrCa 5 categories of <1.66%, 1.66e3.0%, and >3.0% were 0.17%, 0.24%, and 0.39%, respectively (probability value trend, .03), whereas for Part D the rates were 0.36%, 0.45%, and 0.85%, respectively (probability value trend, .009). Among ever-users (n¼67), 17.9% of the women had a daily use rate of >75%; 38.8% of the women had a rate of <25%, and 43.3% of the women had a rate of 25e75%. Concordance between the MUQ and Part D data sources on tamoxifen usage was good (kappa¼0.83). In all women, tamoxifen use significantly increased from 2010e2014 (odds ratio, 1.18; 95% confidence interval, 1.06e1.32) for the current year compared with previous year (Table 3) . 
Use of other drugs
Comment
This analysis of an older cohort showed that use of raloxifene overall was low: 2.5% in a short-term period (1 month) and 4.2% over a longer (5-year) period. Among women both with and without osteoporosis, raloxifene use increased significantly with breast cancer risk level. Based on longer term (Part D) data, among women without osteoporosis who were more likely to use raloxifene for breast cancer prevention, use increased 2-fold for the highest (3%) compared with lowest (<1.66%) breast cancer risk group, although even in this highest risk group, usage (from Part D data) was only 5.2%. Tamoxifen use was substantially lower here than raloxifene use. This was presumably due to the better side-effect profile of raloxifene.
Interestingly, there was a statistically significant decrease in raloxifene use from 2010e2014 and specifically from the year before (2012) to the year after (2014) the USPSTF "B" recommendation concerning breast cancer riskereducing medications. Further, it decreased not only in women overall but also in those women were recommended by the USPSTF for raloxifene use, namely, those with a 3% 5-year risk of breast cancer who had a 23% reduction in use from 2012e2014. This decrease from 2012e2014 was not due to women discontinuing raloxifene use because of duration of use because discontinuation rates were similar, if slightly lower, among women who had been using raloxifene 5 years previously as for women who had not been using raloxifene 5 years previously. Note that the USPSTF recommendation statement shows the standard dose of raloxifene for breast cancer risk reduction as being 60 mg for 5 years, based on the duration of use in the major clinical trials of raloxifene. Data from the MUQ, though, shows that most women (75%) who used raloxifene currently had been using for over 5 years.
It is important to note that this decreasing trend over time was for a Raloxifene rates over time Raloxifene use (prescriptions filled) by calendar year from Part D claims data. The usage rate in a given year was calculated as the proportion of women with full coverage in that year who had at least 1 prescription filled in that year. The solid black line indicates all women; the solid blue line and dotted line indicate women with and without osteoporosis, respectively; the red line indicates all women with 5-year breast cancer risk of at least 3%; and the purple line indicates women with at least a 3% breast cancer risk and no osteoporosis. ajog.org GYNECOLOGY Original Research cohort of older women, all well past menopause at the start of the observation period (2010). Therefore, these data are not informative about whether women who were newly reaching postmenopausal status had decreasing rates in the initiation of raloxifene use over this time period.
There is relatively little literature on tamoxifen and especially raloxifene use for breast cancer prevention in the general population outside of a chemoprevention trial or a study examining decision aids and/or attitudes about breast cancer chemoprevention. 8 A study that used the 2010 National Health Interview Survey found that 0.9% of women who were 50e79 years old were taking raloxifene; approximately onefourth of them were taking the drug for breast cancer prevention. 9 Use of tamoxifen for breast cancer prevention among women aged 35e79 years in the National Health Interview Survey was 0.03%. This rate of raloxifene use is lower than that reported here of 2.5% for women 65e84 years old.
Studies of decision aids or attitudes about raloxifene and tamoxifen generally show low levels of interest in taking either drug. In1 study of a decision aid, 5.7% of intervention and 3.2% of control arm subjects indicated an intention to take a breast cancer prevention drug, but only 0.5% of intervention arm and no control subjects actually took either drug. 12 A majority of the women in each arm did not perceive significant benefits from these drugs. In another study, factors that influence the decision to take raloxifene were the time having to take it (women preferred 1 year vs 5 years), the risk of side-effects, and not having a test available to determine whether the drugs were working. 13 Another study showed that, among women the discussed breast cancer risk-reducing medications with their health care provider, the provider's recommendation was the most important determinant of intention to use tamoxifen or raloxifene.
14 It has also Original Research GYNECOLOGY ajog.org been suggested that, in the setting of a preventive intervention, formal quantitative comparison of risk reduction vs adverse effects may be less important than subjects' feelings and that, although "relief " is an important motivator for some preventive behaviors (eg, mammography), taking tamoxifen or raloxifene is unlikely to afford a sense of relief. 15, 16 Surveys generally have found low rates of prescribing breast cancer chemopreventive agents among physicians. 17, 18 Barriers to physicians, and especially those in primary care, in recommending breast cancer chemoprevention include difficulty in identifying patients who might benefit from it, lack of time to discuss it with patients, lack of knowledge in risk-reducing medication options, unfamiliarity with the Gail model and breast cancer risk prediction, insufficient training in risk counselling, and concerns about side-effects. 18, 19 Because of findings like these in both patients and physicians, investigators are exploring dual interventions to provide personalized information to both the patient and healthcare provider to increase informed decision-making and chemoprevention uptake. 20 Other suggestions for increasing the use of breast cancer chemopreventive agents include incorporating training on this topic into residency and fellowship programs and having the breast cancer advocacy community take a more active role in the promotion of chemoprevention. 21 In contrast to the relatively low rates of raloxifene use for breast cancer risk reduction, the use of statins for cardiovascular disease prevention was high, 58% overall. Strikingly, for women at both high cardiovascular risk and high breast cancer risk (BrCa 5 3.0%), the use rate for statins was 13-fold higher than for raloxifene (76.3% vs 5.8%). There is little or no literature on comparative attitudes of patients or physicians on the use of statins vs breast cancer riskereducing medications; however, factors that may be affecting the difference in usage rates include physician attitudes and knowledge, perceived risks of breast cancer vs cardiovascular disease, and real and believed side-effect profiles of the medications. In addition, statins have a wellvalidated intermediate endpoint (cholesterol level) that can be evaluated as a marker of effectiveness, whereas there is no such intermediate endpoint for raloxifene. Breast density has been shown to be a potential surrogate for tamoxifen efficacy; however, this same relationship has not been shown for raloxifene, potentially because most of the studies were retrospective and enrolled mainly women with low mammographic density. 22, 23 Interestingly, the new statin guidelines indicate use for those with 10-year cardiovascular disease risk to be 7.5%. 24 For a 5-year period, that would translate into a risk of roughly 3.75%, which is similar to the 3% 5-year breast cancer risk threshold for use that is recommended by the USPSTF.
A limitation of this study is that the cohort analyzed here, all of whom were enrolled in the PLCO trial, were volunteers for a cancer screening trial and were more highly educated and health conscious than the general population in their age group; additionally, their rate of mammography use was also higher than average. 25, 26 Therefore, the rates observed here of raloxifene and tamoxifen use may overestimate rates in the overall population. Another limitation is that the indication for raloxifene use, whether for osteoporosis or breast cancer prevention or both, was not known. An indication for breast cancer risk reduction can be inferred, however, in a subset of users based on the gradient of increasing usage rates with increasing breast cancer risk. There were some missing data in terms of calendar years with no Part D coverage, but the rate was Usage rates of statins and raloxifene by risk level
Rates of use of raloxifene (blue bars) and statins (black bars) from Part D data by cardiovascular disease risk level and five-year breast cancer risk category. High risk of cardiovascular disease risk is defined as history of diabetes mellitus, high cholesterol, heart attack, or stroke; low risk is defined as all women not at high risk. 
Conclusion
The use of raloxifene in this Medicareaged cohort was low overall but increased modestly with breast cancer risk. Raloxifene use in this cohort significantly declined in the period from before to after the USPSTF "B" recommendation for breast cancer chemoprevention. The use of tamoxifen was very low. n
